Chemistry Ventures Raises $500M on Pure Faith and Pedigree

Chemistry Ventures, founded by alumni from Bessemer Venture Partners, Index Ventures, and Andreessen Horowitz, is raising $500 million for its second fund. This is not a typo. The firm, which apparently has never heard of the concept of "proof of concept," is now seeking half a billion dollars in fresh capital despite the complete absence of public information regarding the performance, exits, or even basic survival status of its inaugural fund. Welcome to the VC sector, where your last job title is apparently a stronger credential than your actual investment returns.

What makes this particularly arresting is the studied silence around Chemistry Ventures' first fund performance. The firm launched with considerable fanfare—the pedigree alone could fill a Wikipedia disambiguation page—yet has produced no announced exits, no public portfolio wins, and no demonstrable evidence that deploying capital through this vehicle was anything other than an expensive learning experience. The firm exists in a state of productive ambiguity, which in venture capital is apparently indistinguishable from success. Your limited partners' emails asking "how are our companies doing?" are, one presumes, being answered with carefully constructed noncommittal updates.

This follows a well-worn playbook in the industry: gather enough impressive business cards, raise a modest first fund, disappear for five years, then emerge claiming that "the portfolio is performing well relative to market conditions" (a phrase meaning nothing and everything simultaneously). The fact that Chemistry Ventures has managed to attract $500 million for round two suggests that either their LPs have extraordinarily short institutional memory or that the pedigree problem is real—when you've worked at three of the most successful firms in venture history, people seem willing to assume the alpha was in you rather than your employer's brand, market timing, and portfolio size.

The firm's fundraising materials likely emphasize "deep domain expertise," "sector focus," and "founder-friendly partnership models"—the holy trinity of VC buzzwords that mean "we read Marc Andreessen's blog" and "we will attend your board meetings." These are the coded phrases that transform an unproven track record into a compelling investment thesis. Chemistry Ventures is apparently composed of people who were present during successful investments, which they have apparently internalized as meaning they caused those investments to succeed.

What could go wrong is straightforward: the first fund could underperform, second fund capital dries up in a market downturn, the team discovers that they were less responsible for their employers' success than they imagined, or all three occur simultaneously. The VC model depends on outsized returns from a small number of bets; the firm has already taken one swing with undisclosed results. Now they're asking for $500 million to swing again.

This deal exemplifies modern venture capital's fundamental faith in pedigree over performance. The industry has essentially concluded that working at a successful firm is a sufficient qualification for running an unsuccessful one. Chemistry Ventures isn't alone in this—it's just notably transparent about it, raising the kind of capital that typically requires at least some publicly defensible evidence of competence.

In other sectors, this would be called a confidence game. In venture capital, it's called "deploying capital behind great operators."